Skip to content

A study to test whether BI 690517 in combination with empagliflozin helps people with heart failure

Heart Failure

The purpose of this study is to find out whether BI 690517 (investigational drug) in combination with empagliflozin helps people with heart failure.

Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are:

- BI 690517 and empagliflozin

- Placebo and empagliflozin

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:
The main eligibility criteria are chronic heart failure (HF) diagnosed ≥3 months before screening, New York Heart Association (NYHA) class II-IV, structural heart abnormality, and elevated NT-proBNP.

Eligible participants will be at least 18 years of age, male or female, and already receiving the best possible standard of care.
Exclusion Criteria:
Potential participants will be excluded if receiving or need to receive an mineralocorticoid receptor antagonist (MRA) [e.g. spironolactone, eplerenone, finerenone].

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Rebecca Cairns

[email protected]
780-613-5008
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00147172